## PATENT COOPERATION TREATY

# PCT

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220
X-16250	ACTION as we	Il as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US2004/038221	01/12/2004	12/12/2003
Applicant		
ŕ		
ELI LILLY AND COMPANY		·
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Au ansmitted to the International Bureau.	thority and is transmitted to the applicant
This International Search Report consists	of a total of sheets.	·
X It is also accompanied by	a copy of each prior art document cited in thi	s report.
	international search was carried out on the ba	asis of the international application in the
The international this Authority (Ru		slation of the international application furnished to
b. With regard to any nucleo	otide and/or amino acid sequence disclosed	d in the International application, see Box No. I.
2. X Certain claims were fou	nd unsearchable (See Box II).	
3. X Unity of invention is lac	king (see Box III).	
4. With regard to the title,		
the text is approved as su	bmitted by the applicant.	
X the text has been establis	hed by this Authority to read as follows:	
	NE REUPTAKE INHIBITORS FOR ROL DISORDERS AND PERSONALI	
·		·
5. With regard to the abstract,		
X the text is approved as su	bmitted by the applicant.	
	thed, according to Rule 38.2(b), by this Autho om the date of mailing of this international sea	rity as it appears in Box No. IV. The applicant irch report, submit comments to this Authority.
6. With regard to the drawings,		·
a. the figure of the drawings to be p	oublished with the abstract is Figure No.	<del></del>
as suggested by	he applicant.	
as selected by thi	s Authority, because the applicant failed to su	uggest a figure.
	s Authority, because this figure better charact	terizes the invention.
b. X none of the figures is to b	e published with the abstract.	•

Form PCT/ISA/210 (first sheet) (January 2004)

International Application No

PCT/US2004/038221 A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/138 A61K31/4468 A61K31/5375 A61K31/4704 A61K31/538 A61K31/5415 A61K31/4025 A61K31/40 A61K31/445 A61K31/439 A61K31/5377 A61P15/12 A61P25/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, SCISEARCH, WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No WO 2005/047272 A (ELI LILLY AND COMPANY; CAMPBELL, GORDON, IAIN; CASES-THOMAS, MANUEL, J) 26 May 2005 (2005-05-26) Ε 1,2 abstract page 19, line 1 - page 20, line 7 √WO 2005/023802 A (ELI LILLY AND COMPANY; Ε 1,2 CLARK, BARRY, PETER; GALLAGHER, PETER, THADDEUS) 17 March 2005 (2005-03-17) abstract page 16, line 28 - page 17, line 31; claims Further documents are listed in the continuation of box C. Patent family members are listed in annex Special categories of cited documents: later document published after the International filing date or priority date and not in conflict with the application but cled to understand the principle or theory underlying the document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docudocument referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed \*&\* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 22 July 2005 01/08/2005 Name and mailing address of the ISA Authorized officer European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Ryswijk
Tel (+31-70) 340-2040. Tx 31 651 epo nl,
Fax: (+31-70) 340-3016

4

Hoff, P

International Application No PCT/US2004/038221

C (Caption	PARTY PARTY CONCINENT TO BE BE DIAME	FC170320047038221
Category *	etion) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
P,X	WO 2004/035058 A (WYETH; DEECHER, DARLENE, COLEMAN; MERCHENTHALER, ISTVAN, JOSEPH; LEVEN) 29 April 2004 (2004-04-29) abstract page 4, paragraph 11 - paragraph 12 page 10, paragraph 36 claims 1,6,23	1-3
P,X	MO 2004/035036 A (WYETH; DEECHER, DARLENE, COLEMAN; MERCHENTHALER, ISTVAN, JOSEPH) 29 April 2004 (2004-04-29) abstract page 5, paragraph 19 - page 6, paragraph 23; claims 1,4,13	1-3
A	WO 02/078691 A (ELI LILLY AND COMPANY; WALLACE, OWEN, BRENDAN; GARNETT, TIMOTHY, JOHN) 10 October 2002 (2002-10-10) the whole document	1-3
A	LOPRINZI C L ET AL: "Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial" LANCET, vol. 356, no. 9247, 16 December 2000 (2000-12-16), pages 2059-2063, XP004264310 ISSN: 0140-6736 the whole document	1-3
<b>A</b> .	✓QUELLA S K ET AL: "PILOT EVALUATION OF VENLAFAXINE FOR THE TREATMENT OF HOT FLASHES IN MEN UNDERGOING ANDROGEN ABLATION THERAPY FOR PROSTATE CANCER" JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 162, no. 1, July 1999 (1999-07), pages 98-102, XP009026289 ISSN: 0022-5347 the whole document	1-3
A	WO 02/40006 A (ELI LILLY AND COMPANY; THOMASSON, HOLLY, READ; MICHELSON, DAVID; READ,) 23 May 2002 (2002-05-23) the whole document	1-3
A	EP 0 534 756 A (ELI LILLY AND COMPANY) 31 March 1993 (1993-03-31) the whole document	1-3
A	\( \sqrt{WO} \) 03/037334 A (MERCK & CO., INC; ALVES, STEPHEN, E; HAMMOND, MILTON, L; WRIGHT, SAMUE) 8 May 2003 (2003-05-08) page 7, line 10 - page 8, line 9; claims 1-4; example 4	1,2
	-/	

International Application No PCT/US2004/038221

C-(Continua	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category •	Cdation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
P,A	WO 2004/052858 A (ELI LILLY AND COMPANY; CLARK, BARRY, PETER; CASES-THOMAS, MANUEL, JAVI) 24 June 2004 (2004-06-24) abstract; claims; examples	*	1-3
P,A	WO 2004/018441 A (ELI LILLY AND COMPANY; CASES-THOMAS, MANUEL, JAVIER; HAUGHTON, HELEN,) 4 March 2004 (2004-03-04) abstract; claims		1,2
P,A	WO 2004/017977 A (ELI LILLY AND COMPANY; WALTER, MAGNUS, WILHELM; CLARK, BARRY, PETER; G) 4 March 2004 (2004-03-04) abstract; claims		1,2
-			
	•		
*			
	*		
			· 7

International application No. PCT/US2004/038221

# INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
Although claims 1 and 3 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.	
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	-
see additional sheet	
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
	,
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
1-3 (partially), relating to inventions 1 and 4	
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:	
	•
Remark on Protest The additional search fees were accompanied by the applicant's protest.	
The additional search lees were accompanied by the applicant's protest.  X No protest accompanied the payment of additional search fees.	

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-3 (partially)

Use of atomoxetine or a compound of formula (I) for treating hot flashes and vasomotor symptoms

2. claims: 1-2 (partially)

Use of racemic reboxetine or (S,S) reboxetine for treating hot flashes and vasomotor symptoms

3. claims: 1-2 (partially)

Use of a compound of formula (IA) for treating hot flashes and vasomotor symptoms

4. claims: 1-2 (partially)

Use of a morpholine derivative of formula (IB),(IC),(IG),(IH) for treating hot flashes and vasomotor symptoms  ${\bf S}_{\rm c}$ 

5. claims: 1-2 (partially)

6. claims: 1-2(partially)

Use of a compound of formula (IE) for treating hot flashes and vasomotor symptoms

7. claims: 1-2 (partially)

8. claims: 1-3 (partially)

Use of a selective norepinephrine reuptake inhibitor such as defined in claim 1 for treating impulse control disorders

9. claims: 1-3 (partially)

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Use of a selective norepinephrine reuptake inhibitor such as defined in claim 1 for treating personality change due to general medical condition  $\frac{1}{2} \int_{-\infty}^{\infty} \frac{1}{2} \left( \frac{1}{2} \int$ 

information on patent family members

International Application No PCT/US2004/038221

				PC1/US2U04/U38221		
Patent document cited in search rep		Publication date	:	Patent family member(s)		Publication date
WO 20050472	72 A	26-05-2005	WO	2005047272	A1	26-05-2005
WO 20050238	02 A	17-03-2005	WO	2005023802	A1	17-03-2005
WO 20040350	58 A	29-04-2004	US	2004152710	A1	05-08-2004
			AU	2003282861	A1	04-05-2004
			ΑU	2003282862	A1	04-05-2004
			CA	2502021	A1	29-04-2004
			CA	2502032	A1	29-04-2004
			EP	1551413	A1	13-07-2005
	•		EP	1551379	A1	13-07-2005
			WO	2004035058	. A1	29-04-2004
			WO	2004035035	A1	29-04-2004
•			US	2004143008		22-07-2004
		· 	WO	2005037260	A2	28-04-2005
WO 20040350	36 A	29-04-2004	US	2004180879		16-09-2004
			ΑU	2003282830		04-05-2004
			CA	2502027		29-04-2004
			EP	1551380		13-07-2005
			WO	2004035036	A1 	29-04-2004
WO 02078691	. A	10-10-2002	CA	2442410	A1	10-10-2002
			EP	1383495		28-01-2004
•			JP	2004525940		26-08-2004
	. •		WO	02078691	A1	10-10-2002
WO 0240006	A	23-05-2002	AU	1775702		27-05-2002
•			BR	0115301		14-12-2004
•		•	CA	2426069		23-05-2002
	•		CZ	20031339		15-10-2003
			EP	1395253		10-03-2004
			HR	20030384		31-08-2003
			ΗU	0301863		29-09-2003
			JP	2004529073		24-09-2004
			MX	PA03004190		22-09-2003
			NO PL	20032156 366119		13-05-2003 24 <b>-</b> 01-2005
			SK	5422003		02-12-2003
			WO Sk	0240006		23-05-2002
			ZA	200303738		26-08-2004
EP 0534756	Α	31-03-1993	US	5281624		25-01-1994
			AT	124934		15-07-1995
			AU AU	655075 2537092		01-12-1994 01-04-1993
•			BR	1100384		31-08-1999
			BR	9203743		20-04-1993
			CA	2079161		28-03-1993
			CA	2079162		28-03-1993
			CN	1071416		28-04-1993
			CZ	9202908		14-04-1993
			DE	69203424		17-08-1995
			DE	69203424		11-01-1996
			DK	537915		27-11-1995
			EP	0534756		31-03-1993
			EP	0537915		21-04-1993
			EP	0591584	L A1	13-04-1994

Information on patent family members

International Application No PCT/US2004/038221

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0534756	A		FI	924305 A	28-03-1993
		•	HU	65375 A2	02-05-1994
			ΙL	103277 A	20-11-1997
			JP	3256291 B2	12-02-2002
			JP	5201961 A	10-08-1993
			JP	5238996 A	17-09-1993
			KR	221180 B1	15-09-1999
			MX	9205433 A1	01-03-1993
			NO	923710 A	,B, 29-03-1993
			NZ	244460 A	26-10-1994
			SK	290892 A3	14-02-2000
•			RU	2057120 C1	27-03-1996
			ZA	9207240 A	22-03-1994
WO 03037334	Α	08-05-2003	WO	03037334 A1	08-05-2003
			US	2004259850 A1	23-12-2004
WO 2004052858	Α	24-06-2004	AU	2003290735 A1	30-06-2004
			WO	2004052858 A2	24-06-2004
WO 2004018441	A	04-03-2004	AU	2003268024 A1	11-03-2004
			EP	1534694 A1	01-06-2005
			WO	2004018441 A1	04-03-2004
WO 2004017977	Α	04-03-2004	AU	2003269923 A1	11-03-2004
, =	• •		EP	1534291 A2	01-06-2005
			WO	2004017977 A2	04-03-2004